WO2006125201A3 - Anticorps anti-muteines mcp-1 biotine-pegylees, compositions, procedes et utilisations correspondants - Google Patents

Anticorps anti-muteines mcp-1 biotine-pegylees, compositions, procedes et utilisations correspondants Download PDF

Info

Publication number
WO2006125201A3
WO2006125201A3 PCT/US2006/019625 US2006019625W WO2006125201A3 WO 2006125201 A3 WO2006125201 A3 WO 2006125201A3 US 2006019625 W US2006019625 W US 2006019625W WO 2006125201 A3 WO2006125201 A3 WO 2006125201A3
Authority
WO
WIPO (PCT)
Prior art keywords
mcp
pegylated
biotin
antibodies
muteins
Prior art date
Application number
PCT/US2006/019625
Other languages
English (en)
Other versions
WO2006125201A2 (fr
Inventor
Marian F Kruszynski
Raymond Sweet
Ping Tsui
Nicole Stowell
Jinguan Luo
Original Assignee
Centocor Inc
Marian F Kruszynski
Raymond Sweet
Ping Tsui
Nicole Stowell
Jinguan Luo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc, Marian F Kruszynski, Raymond Sweet, Ping Tsui, Nicole Stowell, Jinguan Luo filed Critical Centocor Inc
Publication of WO2006125201A2 publication Critical patent/WO2006125201A2/fr
Publication of WO2006125201A3 publication Critical patent/WO2006125201A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Cette invention concerne des mutéines MCP-1, y compris des parties ou des variantes spécifiées de ces mutéines, qui peuvent éventuellement être PEGylées ou biotine-PEGylées. Cette invention concerne en outre des procédés de synthèse chimique pour produire ces mutéines MCP-1 et des conjugués correspondants. Cette invention concerne l'utilisation de ces mutéines et, en particulier, l'utilisation des conjugués biotinylés pour sélectionner des anticorps de neutralisation contre la protéine MCP-1 humaine, ainsi que les anticorps ainsi sélectionnés. Ces anticorps sont spécifiques pour un épitope conservé sur une mutéine MCP-1 native conservée dans la ou les protéines mutéines MCP-1 biotinylées et PEGylées ou un fragment de celle(s)-ci..
PCT/US2006/019625 2005-05-19 2006-05-19 Anticorps anti-muteines mcp-1 biotine-pegylees, compositions, procedes et utilisations correspondants WO2006125201A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68262005P 2005-05-19 2005-05-19
US60/682,620 2005-05-19

Publications (2)

Publication Number Publication Date
WO2006125201A2 WO2006125201A2 (fr) 2006-11-23
WO2006125201A3 true WO2006125201A3 (fr) 2007-07-12

Family

ID=37432200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019625 WO2006125201A2 (fr) 2005-05-19 2006-05-19 Anticorps anti-muteines mcp-1 biotine-pegylees, compositions, procedes et utilisations correspondants

Country Status (1)

Country Link
WO (1) WO2006125201A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
US8449489B2 (en) 2006-05-12 2013-05-28 Ith Immune Therapy Holdings Ab Method and means for treating inflammatory bowel disease
EP2041568A4 (fr) * 2006-06-15 2009-08-12 Antagonistes de ccr2 destine au traitement d'un rejet chronique de transplantation d'organe
EP2068920A2 (fr) * 2006-10-05 2009-06-17 Centocor Ortho Biotech, Inc. Antagonistes de ccr2 pour le traitement de la fibrose
FI20075059A0 (fi) 2007-01-29 2007-01-29 Valtion Teknillinen Allergeeniä sitovat monoklonaaliset IgE-vasta-aineet ja hypoallergeenit:tyypin l lgE:n ja allergeenin immunokompleksivuorovaikutus
AU2008269954A1 (en) * 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- MCP-1 antibodies, compositions, methods and uses
US8518406B2 (en) 2008-08-20 2013-08-27 Probiodrug Ag Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (MCP-1 N1pE)
EA023912B1 (ru) * 2008-09-10 2016-07-29 АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ Лечение воспалительных состояний
ES2821375T3 (es) * 2011-06-13 2021-04-26 Tla Targeted Immunotherapies Ab Tratamiento de afecciones respiratorias
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
MX2018001522A (es) * 2015-08-05 2018-03-15 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA2152141A1 (fr) * 1995-06-19 1996-12-20 Ian-Clark Lewis Antagonistes de la proteine mcp-1 de monocyte
US6423685B1 (en) * 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA2152141A1 (fr) * 1995-06-19 1996-12-20 Ian-Clark Lewis Antagonistes de la proteine mcp-1 de monocyte
US6423685B1 (en) * 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLARK-LEWIS I. ET AL.: "Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs", J. BIOL. CHEM., vol. 266, no. 34, 5 December 1991 (1991-12-05), pages 23128 - 23134, XP000576162 *
GONG J.-H. ET AL.: "Antagonists of Monocyte Chemoattractant Protein 1 Identified by Modification of Functionally Critical NH2-terminal residues", J. EXP. MED., vol. 181, February 1995 (1995-02-01), pages 631 - 640, XP000569550 *
HEMMERICH S. ET AL.: "Identification of Residues in the Monocyte Chemotactic Protein-1 That Contact the MCP-1 Receptor, CCR2", BIOCHEMISTRY, vol. 38, 15 September 1999 (1999-09-15), pages 13013 - 13025, XP002319264 *
KRUSZYNSKI M. ET AL.: "Synthetic, site-specific biotinylated analogs of human MCP-1", J. PEPTIDE SCI., vol. 12, no. 5, May 2006 (2006-05-01), pages 354 - 360, XP003015235 *
STEITZ S.A. ET AL.: "Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis", FEBS LETTERS, vol. 430, 1998, pages 158 - 164, XP004258051 *

Also Published As

Publication number Publication date
WO2006125201A2 (fr) 2006-11-23

Similar Documents

Publication Publication Date Title
WO2006125201A3 (fr) Anticorps anti-muteines mcp-1 biotine-pegylees, compositions, procedes et utilisations correspondants
LTC1971366I2 (lt) Žmogaus anti-IL-23 antikūnai, kompozicijos, metodai ir panaudojimai
TWI370136B (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
WO2007007173A3 (fr) Nouveaux anticorps anti-madcam
HK1109636A1 (en) Human antibodies and proteins
WO2005105129A3 (fr) Epitopes associes a une maladie coeliaque
WO2009136286A3 (fr) Anticorps à réaction croisée anti-il-17a/il-17f et leurs procédés d'utilisation
WO2007059430A3 (fr) Moésine, cavéoline 1 et protéine 1 associée à yes en tant que marqueurs prédictifs de la réponse au dasatinib dans les cancers du sein
WO2007076032A3 (fr) Compositions et procédés de production d'une composition
WO2007056470A3 (fr) Antagonistes de la neuropiline
WO2006026759A3 (fr) Antagonistes anti-beta7 humanises et utilisations de ceux-ci
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
WO2006119107A3 (fr) Agents de fixation
WO2006119062A3 (fr) Epitopes
WO2004092215A3 (fr) Methodes therapeutiques utilisant des agents liants specifiques de l'angiopoietine-2 humaine
IL177922A0 (en) Modified bouganin proteins, cytotoxins and methods and uses thereof
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2005091856A8 (fr) Proteines derivees de l'immunoglobuline anti-il-13 associees a l'asthme, composition, procedes associes et leur utilisation
WO2006050826A3 (fr) Traitement de mastites
EP1959999A4 (fr) Polynucleotides et polypeptide de kv1.3 humain, preparations comprenant lesdites substances et methodes d'utilisation
IL190712A0 (en) Polynucleotides and polypeptide of human kv1.3, compositions comprising same and methods of using same
WO2007021733A3 (fr) Procedes et compositions permettant d'ameliorer le pliage de proteines
WO2006008266A3 (fr) Proteines de liaison au facteur xi

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06784445

Country of ref document: EP

Kind code of ref document: A2